Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,deferredLongTermLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,IMNM,37883000.0,11757300,1979000,,-3898000,,-3898000,1918000,0,-3897000,-3897000,,-2000,,,,0,0,3897000,0,-1000,,-3898000,-3898000,96174000.0,4710000.0,37883000.0,667000.0,42593000.0,1000.0,-58292000.0,5000.0,100000.0,36276000.0,4571000.0,444000.0,1386000.0,41107000.0,2600000.0,134000.0,2958000.0,,1771000.0,-31000.0,-35000.0,76000.0,-1908000.0,111000.0,-3490000.0,-3535000.0,176000.0,324000.0,-31000.0,,36536000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,14.94,1630526402,0.90999985,14.11,14.97,13.87,63618,USD,NCM,175654064,-14400000,False,False,PRE,2,6.4861,13.87 - 14.97,us_market,0,"Immunome, Inc.",14.03,0.0,0.0,8,11,finmb_108518404,NasdaqCM,"Immunome, Inc.",USD,431490,68271,5.665,0.61078167,9.275 - 63.78,-48.84,-0.7657573,9.275,63.78,1620849600,1620849600,1620849600,15.152286,-0.212286,-0.014010163,22.502718,-7.5627184,-0.33608022,15,America/New_York,EDT,,,,63.78,9.27,15.15,22.5,431.49k,68.27k,11.76M,,8.7M,28.84%,16.57%,227.37k,2.36,2.21%,1.93%,232.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-30.80%,-92.63%,,,,,-12.73M,-19.06M,,,36.28M,3.09,578k,1.53,8.99,,-13.61M,,Value,19341,Healthcare,23,9,10,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",Exton,610 321 3700,PA,8,1609372800,1622505600,10,United States,http://immunome.com,86400,10,665 Stockton Drive,Biotechnology,Suite 300
t-1,IMNM,41345000.0,11757300,1835000,,-4073000,,-4073000,2238000,0,-4073000,-4073000,,-12000,,,,0,0,4073000,0,0,,-4073000,-4073000,95738000.0,3180000.0,41345000.0,,44525000.0,1000.0,-54394000.0,8000.0,100000.0,39766000.0,3038000.0,479000.0,1531000.0,42894000.0,900000.0,134000.0,1187000.0,,-495000.0,-46000.0,-47000.0,39130000.0,-2057000.0,44863000.0,33022000.0,-6062000.0,256000.0,307000.0,-46000.0,-5686000.0,39856000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,14.94,1630526402,0.90999985,14.11,14.97,13.87,63618,USD,NCM,175654064,-14400000,False,False,PRE,2,6.4861,13.87 - 14.97,us_market,0,"Immunome, Inc.",14.03,0.0,0.0,8,11,finmb_108518404,NasdaqCM,"Immunome, Inc.",USD,431490,68271,5.665,0.61078167,9.275 - 63.78,-48.84,-0.7657573,9.275,63.78,1620849600,1620849600,1620849600,15.152286,-0.212286,-0.014010163,22.502718,-7.5627184,-0.33608022,15,America/New_York,EDT,,,,63.78,9.27,15.15,22.5,431.49k,68.27k,11.76M,,8.7M,28.84%,16.57%,227.37k,2.36,2.21%,1.93%,232.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-30.80%,-92.63%,,,,,-12.73M,-19.06M,,,36.28M,3.09,578k,1.53,8.99,,-13.61M,,Value,19341,Healthcare,23,9,10,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",Exton,610 321 3700,PA,8,1609372800,1622505600,10,United States,http://immunome.com,86400,10,665 Stockton Drive,Biotechnology,Suite 300
t-2,IMNM,-49085000.0,11757300,1644000,,-8377000,,-8377000,1174000,0,-2818000,-2818000,,-10000,,,,0,0,2818000,0,-5559000,,-8377000,-8377000,1236000.0,5628000.0,-49085000.0,1165000.0,11983000.0,,-50321000.0,11000.0,2759000.0,6744000.0,5406000.0,449000.0,1741000.0,7483000.0,,211000.0,2627000.0,2500000.0,125000.0,-124000.0,-88000.0,-393000.0,-118000.0,4000.0,-3045000.0,-2528000.0,177000.0,5665000.0,-124000.0,-309000.0,2077000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,14.94,1630526402,0.90999985,14.11,14.97,13.87,63618,USD,NCM,175654064,-14400000,False,False,PRE,2,6.4861,13.87 - 14.97,us_market,0,"Immunome, Inc.",14.03,0.0,0.0,8,11,finmb_108518404,NasdaqCM,"Immunome, Inc.",USD,431490,68271,5.665,0.61078167,9.275 - 63.78,-48.84,-0.7657573,9.275,63.78,1620849600,1620849600,1620849600,15.152286,-0.212286,-0.014010163,22.502718,-7.5627184,-0.33608022,15,America/New_York,EDT,,,,63.78,9.27,15.15,22.5,431.49k,68.27k,11.76M,,8.7M,28.84%,16.57%,227.37k,2.36,2.21%,1.93%,232.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-30.80%,-92.63%,,,,,-12.73M,-19.06M,,,36.28M,3.09,578k,1.53,8.99,,-13.61M,,Value,19341,Healthcare,23,9,10,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",Exton,610 321 3700,PA,8,1609372800,1622505600,10,United States,http://immunome.com,86400,10,665 Stockton Drive,Biotechnology,Suite 300
t-3,IMNM,-35630000.0,11757300,2115000,,-2677000,,-2677000,540000,0,-2655000,-2655000,,-8000,,,,0,0,2655000,0,-22000,,-2677000,-2677000,1114000.0,3130000.0,-35630000.0,,12214000.0,1000.0,-41944000.0,18000.0,229000.0,9789000.0,2789000.0,390000.0,1794000.0,10191000.0,,323000.0,1422000.0,,314000.0,-55000.0,-151000.0,844000.0,-10000.0,1500.0,-1275000.0,-2064000.0,163000.0,146000.0,-55000.0,-13500.0,7402000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,14.94,1630526402,0.90999985,14.11,14.97,13.87,63618,USD,NCM,175654064,-14400000,False,False,PRE,2,6.4861,13.87 - 14.97,us_market,0,"Immunome, Inc.",14.03,0.0,0.0,8,11,finmb_108518404,NasdaqCM,"Immunome, Inc.",USD,431490,68271,5.665,0.61078167,9.275 - 63.78,-48.84,-0.7657573,9.275,63.78,1620849600,1620849600,1620849600,15.152286,-0.212286,-0.014010163,22.502718,-7.5627184,-0.33608022,15,America/New_York,EDT,,,,63.78,9.27,15.15,22.5,431.49k,68.27k,11.76M,,8.7M,28.84%,16.57%,227.37k,2.36,2.21%,1.93%,232.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-30.80%,-92.63%,,,,,-12.73M,-19.06M,,,36.28M,3.09,578k,1.53,8.99,,-13.61M,,Value,19341,Healthcare,23,9,10,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",Exton,610 321 3700,PA,8,1609372800,1622505600,10,United States,http://immunome.com,86400,10,665 Stockton Drive,Biotechnology,Suite 300
